Association of galectin-3 in systemic lupus erythematosus: A systematic review and meta-analysis.

In 30 seconds

This systematic review and meta-analysis evaluated the association between circulating galectin-3 levels and systemic lupus erythematosus (SLE). The analysis included seven studies and found that patients with SLE had significantly higher circulating galectin-3 levels compared to healthy controls, with a mean difference of 8.48 (95% CI: 3.84-13.12; p < 0.0001).

Key findings

• Patients with SLE had significantly higher circulating galectin-3 levels than healthy controls (mean difference = 8.48).
• The analysis included seven eligible studies assessing galectin-3 levels.
• Substantial heterogeneity was observed across studies (I 2 = 96.93%).
• No publication bias was detected among the studies.

Why it matters

Understanding the role of galectin-3 in SLE could enhance the identification of disease activity and inform future therapeutic strategies. Elevated levels may indicate ongoing inflammation and organ damage.